Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

PRIMARY Ancillary Substudy

NCT: NCT07103733 · ACTIVE_NOT_RECRUITING

NCT IDNCT07103733
StatusACTIVE_NOT_RECRUITING
Start Date2023-10-16
Completion2027-06-30
SponsorAnnetine Gelijns (OTHER)
First posted
Last updated

Brief Summary

The PRIMARY trial (NCT05051033), which compares mitral valve repair (MVr) to transcatheter-edge-to-edge-repair (TEER), offers a platform for conducting mechanistic studies to develop early insights into the pathophysiological processes by which mitral valve prolapse (MVP) can impact left ventricular (LV) myocardial structure and function, and, thereby, predispose to arrhythmias and sudden death. Such insights are key to identifying interventions to reduce the long-term sequelae of heart failure (HF) and arrhythmias, as well as delineate optimal therapeutic approaches for different patient sub-groups.

Frequently Asked Questions

What is PRIMARY Ancillary Substudy?

PRIMARY Ancillary Substudy is a clinical trial registered under NCT07103733. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07103733?

The current status of NCT07103733 (PRIMARY Ancillary Substudy) is: ACTIVE_NOT_RECRUITING.

When did PRIMARY Ancillary Substudy start?

PRIMARY Ancillary Substudy started on 2023-10-16.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.